Damora Therapeutics, Inc. (DMRA)
$18.56-8.39%Close
SELLCRISIS · day 21
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.1B
- Beta
- 1.44
- P/E (TTM)
- -0.15
- Short % float
- 11.48%
- Days to cover
- 4.8
- SI change
- +0.0%
- 1W
- -5.06%
- 1M
- -34.62%
- vs SPY 1W
- -4.93%
- vs SPY 1M
- -37.13%
Industry peers
FMP comparable companies · ranked by market cap
- GMABBUYGenmab A/S$22.5BBULLQ 21$36.57-2.14%
- INCYSELLIncyte Corporation$22.0BBEARQ 13$108.62-2.46%
- IRONSELLDisc Medicine, Inc.$2.2BCRISISQ 0$56.60-6.42%
- QURESELLuniQure N.V.$1.5BCRISISQ 16$21.28-2.56%
- COAGSELLHemab Therapeutics Holdings, Inc. Common Stock$1.4BQ -10$29.80-1.94%
- RIGLBUYRigel Pharmaceuticals, Inc.$872MBULLQ 9$47.14-3.42%
- GERNSELLGeron Corporation$770MRECOVERYQ 11$1.20-1.64%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on DMRA?
- LOPJLB’s latest quantitative signal on Damora Therapeutics, Inc. (DMRA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is DMRA in?
- Damora Therapeutics, Inc. (DMRA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Damora Therapeutics, Inc. (DMRA) do?
- Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The companyâs lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent …